George C Tsokos Selected Research

George C Tsokos Research Topics

Disease

138	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2024 - 01/2002
48	Autoimmune Diseases (Autoimmune Disease) 01/2024 - 01/2004
29	Inflammation (Inflammations) 01/2024 - 11/2003
19	Ischemia 10/2017 - 06/2002
16	Lupus Nephritis 01/2024 - 07/2008
11	Infections 10/2023 - 03/2005
11	Rheumatoid Arthritis 01/2021 - 05/2002
11	Hemorrhage 01/2016 - 08/2004
9	Nephritis 10/2021 - 09/2009
9	Glomerulonephritis 01/2018 - 09/2008
9	Reperfusion Injury 10/2017 - 01/2004
8	Wounds and Injuries (Trauma) 01/2020 - 03/2007
7	Lung Injury 01/2021 - 02/2005
7	Mesenteric Ischemia 01/2017 - 12/2003
6	Kidney Diseases (Kidney Disease) 11/2023 - 07/2010
6	Arthritis (Polyarthritis) 01/2023 - 11/2003
6	Proteinuria 01/2023 - 02/2011
6	Neoplasms (Cancer) 11/2018 - 10/2005
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 12/2011
5	Rheumatic Diseases (Rheumatism) 01/2024 - 11/2003
5	Psoriatic Arthritis 01/2024 - 12/2011
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 12/2015
4	Experimental Arthritis 01/2023 - 11/2003
4	COVID-19 01/2021 - 06/2020
4	Hypotension (Low Blood Pressure) 01/2013 - 02/2007
4	Hemorrhagic Shock 01/2013 - 02/2007
3	Fibrosis (Cirrhosis) 01/2023 - 07/2015
3	Hypoxia (Hypoxemia) 04/2010 - 04/2003
2	Thrombosis (Thrombus) 01/2023 - 06/2009
2	Virus Diseases (Viral Diseases) 11/2021 - 05/2014
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2020 - 06/2020
2	Acute Lung Injury 11/2020 - 06/2020
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

38	Interleukin-2 (IL2)IBA 10/2022 - 05/2002
36	AutoantibodiesIBA 01/2024 - 01/2004
32	Complement System Proteins (Complement)IBA 11/2023 - 01/2004
26	CytokinesIBA 01/2023 - 09/2005
24	Interleukin-17 (Interleukin 17)IBA 01/2024 - 12/2008
24	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2002
13	AntibodiesIBA 01/2023 - 01/2004
12	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2015 - 01/2002
11	Antigen-Antibody Complex (Immune Complex)IBA 11/2023 - 10/2012
11	CalciumIBA 10/2021 - 12/2003
11	Syk KinaseIBA 01/2021 - 03/2007
10	Cyclic AMP Response Element ModulatorIBA 01/2024 - 12/2011
10	AntigensIBA 01/2023 - 09/2005
9	Transcription Factors (Transcription Factor)IBA 01/2024 - 02/2007
9	zeta chain antigen T cell receptor (TCR zeta chain)IBA 11/2005 - 01/2002
7	Interleukin-23 (Interleukin 23)IBA 01/2024 - 09/2009
7	Immunoglobulin G (IgG)IBA 01/2023 - 04/2005
7	Messenger RNA (mRNA)IBA 11/2012 - 06/2002
6	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2004
5	Calcium-Calmodulin-Dependent Protein Kinase Type 4IBA 01/2023 - 10/2012
5	KN 93IBA 01/2023 - 02/2011
5	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 05/2002
5	CD55 Antigens (Decay Accelerating Factor)IBA 01/2013 - 09/2007
5	Caspase 3 (Caspase-3)IBA 09/2007 - 12/2003
4	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 10/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2011
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 02/2008
4	AutoantigensIBA 01/2017 - 09/2003
4	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 07/2013 - 11/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2012 - 06/2010
3	anti-dsDNA autoantibodyIBA 01/2023 - 01/2013
3	Calcium-Calmodulin-Dependent Protein KinasesIBA 10/2021 - 12/2011
3	Monoclonal AntibodiesIBA 01/2021 - 09/2005
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2021 - 09/2007
3	LigandsIBA 01/2021 - 05/2014
3	Interferon Type IIBA 12/2020 - 07/2011
3	fostamatinibIBA 11/2020 - 07/2015
3	EnzymesIBA 01/2020 - 05/2014
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 02/2011
3	RNA Splicing FactorsIBA 12/2018 - 01/2013
3	Signaling Lymphocytic Activation Molecule FamilyIBA 01/2017 - 01/2016
3	Complement C3 (C3 Complement)IBA 01/2017 - 09/2007
3	Complement Receptors (Complement Receptor)IBA 10/2015 - 12/2004
3	Therapeutic UsesIBA 11/2014 - 12/2003
3	Immunoglobulin M (IgM)IBA 12/2013 - 02/2009
3	Protein Isoforms (Isoforms)IBA 03/2013 - 05/2010
3	VaccinesIBA 02/2013 - 11/2006
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2011 - 09/2004
3	Adenosine Triphosphate (ATP)IBA 09/2007 - 02/2005
3	geldanamycinIBA 09/2007 - 08/2004
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 09/2007 - 02/2005
2	Immunomodulating AgentsIBA 10/2023 - 01/2023
2	2,6-dinitrotoluene (DNT)IBA 10/2022 - 01/2021
2	GlutaminaseIBA 01/2022 - 11/2019
2	NAD (NADH)IBA 01/2022 - 01/2020
2	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2021 - 12/2018
2	Peptides (Polypeptides)IBA 01/2021 - 01/2017
2	InterferonsIBA 01/2021 - 12/2020
2	Interleukin-12 (IL 12)IBA 01/2021 - 10/2018
2	Mucin-1 (CA 15-3 Antigen)IBA 01/2021 - 06/2020
2	Complement Inactivating AgentsIBA 01/2021 - 09/2005
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2020 - 10/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 01/2018

Therapy/Procedure

16	Therapeutics 10/2023 - 05/2002
6	Resuscitation 01/2013 - 08/2004
3	Intravenous Injections 01/2013 - 07/2011
2	Fecal Microbiota Transplantation 07/2022 - 01/2022